Prasad, Ayush
Gilmore, Emily J.
Kim, Jennifer A.
Begunova, Liza
Olexa, Madelynne
Beekman, Rachel
Falcone, Guido J.
Matouk, Charles
Ortega-Gutierrez, Santiago
Temkin, Nancy R.
Barber, Jason
Diaz-Arrastia, Ramon
de Havenon, Adam
Petersen, Nils H. http://orcid.org/0000-0001-9711-3340
Article History
Received: 1 May 2023
Accepted: 17 November 2023
First Online: 29 December 2023
Conflict of interest
: NHP is supported by the National Institutes of Health - National Institute of Neurological Disorders and Stroke (NIH-NINDS) (K23NS110980) and has received clinical research funding from Liminal Sciences. ADH is supported by NIH-NINDS (K23NS105924), has received investigator-initiated clinical research funding from the AAN, has received consultant fees from Integra and Novo Nordisk, has equity in TitinKM and Certus, and receives author fees from UpToDate. EJG is supported by NIH-NINDS (R01NS117904) and receives consulting fees from UCB. SOG is supported by NIH-NINDS (R01NS127114, R03NS1202228), industry investigator-initiated grants from Stryker Neurovascular, Medtronic, Microvention, Methinks, and VizAi, and Society of Vascular and Interventional Neurology, and consulting fees from Medtronic, Stryker, and Microvention. CCM is supported by NIH-NINDS R21NS119992, receives consulting fees from Microvention-Terumo and Stryker, and speaker fees from Penumbra and Silk Road Medical. NRT and JB are supported by NIH-NINDS (U01NS099084).
: The Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase II trial was approved by the local institutional review board at each participating center, and proxy informed consent was obtained from each study participant. This secondary analysis was performed on deidentified data obtained from the Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase II investigators under a data use agreement.